Catalyst Pharmaceuticals will announce Q3 2025 financial results on November 5, followed by a conference call on November 6.
Quiver AI Summary
Catalyst Pharmaceuticals, Inc. announced it will release its third quarter 2025 financial results on November 5, 2025, after market close. A conference call and webcast to discuss these results and provide a business update will be held on November 6, 2025, at 8:30 AM ET. Interested parties can access the call via a U.S. or international dial-in number or through the Investors section of Catalyst's website, where a replay will also be available for 30 days. Catalyst, headquartered in Coral Gables, Florida, focuses on developing treatments for rare diseases and has been recognized on notable industry lists, including Forbes' 2025 Most Successful Mid-Cap Companies. The company emphasizes patient care and accessibility, with a commitment to expanding its market presence.
Potential Positives
- Catalyst Pharmaceuticals is set to release its third quarter 2025 financial results, indicating transparency and accountability to shareholders.
- The upcoming conference call and webcast for discussing financial results shows the company's commitment to engaging with investors and providing updates on business performance.
- Catalyst has been recognized on notable lists, such as Forbes 2025 list of America's Most Successful Mid-Cap Companies and the 2024 Deloitte Technology Fast 500™, indicating strong market performance and growth potential.
- The company's focus on improving the lives of patients with rare diseases and providing a comprehensive suite of support services demonstrates a strong commitment to patient care and accessibility, which can enhance its brand reputation.
Potential Negatives
- Management's conference call and webcast may indicate potential concerns about financial performance if results are not as expected, suggesting possible volatility in investor confidence.
- The emphasis on "known and unknown risks and uncertainties" in the forward-looking statements may highlight vulnerabilities in Catalyst's future projections, which could worry investors.
- Failure to meet expectations or provide substantial updates during the upcoming conference call could lead to negative market reactions, impacting the company's stock price.
FAQ
When will Catalyst Pharmaceuticals release its Q3 2025 financial results?
Catalyst Pharmaceuticals will release its third quarter 2025 financial results on November 5, 2025, after market close.
What time is the Catalyst Pharmaceuticals conference call?
The conference call to discuss the financial results will begin at 8:30 AM ET on November 6, 2025.
How can I access the Catalyst Pharmaceuticals webcast?
The webcast will be accessible under the Investors section of the Catalyst website at www.catalystpharma.com.
What recognition has Catalyst Pharmaceuticals received recently?
Catalyst was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies.
What is the focus of Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals is focused on developing medicines for rare and difficult-to-treat diseases, improving patient care and accessibility.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CPRX Insider Trading Activity
$CPRX insiders have traded $CPRX stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $CPRX stock by insiders over the last 6 months:
- GARY INGENITO (Chief Med. & Reg. Officer) has made 0 purchases and 2 sales selling 244,000 shares for an estimated $5,775,720.
- PATRICK J MCENANY has made 0 purchases and 2 sales selling 200,000 shares for an estimated $5,217,338.
- STEVE MILLER (Chief Op. & Scientific Officer) sold 115,000 shares for an estimated $2,332,200
- RICHARD J DALY (President and CEO) has made 0 purchases and 2 sales selling 92,970 shares for an estimated $2,213,841.
- BRIAN ELSBERND (Chief Compliance/Legal Officer) has made 0 purchases and 3 sales selling 80,000 shares for an estimated $1,596,200.
- DAVID S TIERNEY sold 26,000 shares for an estimated $525,200
- PREETHI SUNDARAM (Chief Strategy Officer) has made 0 purchases and 2 sales selling 3,924 shares for an estimated $103,648.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CPRX Hedge Fund Activity
We have seen 197 institutional investors add shares of $CPRX stock to their portfolio, and 173 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEERFIELD MANAGEMENT COMPANY, L.P. added 2,879,476 shares (+inf%) to their portfolio in Q2 2025, for an estimated $62,484,629
- AMERICAN CENTURY COMPANIES INC added 1,231,419 shares (+233.9%) to their portfolio in Q2 2025, for an estimated $26,721,792
- MORGAN STANLEY added 788,968 shares (+32.9%) to their portfolio in Q2 2025, for an estimated $17,120,605
- GOLDMAN SACHS GROUP INC removed 723,813 shares (-23.1%) from their portfolio in Q2 2025, for an estimated $15,706,742
- FUNDSMITH LLP added 557,812 shares (+25.9%) to their portfolio in Q2 2025, for an estimated $12,104,520
- BANK OF AMERICA CORP /DE/ added 554,200 shares (+30.6%) to their portfolio in Q2 2025, for an estimated $12,026,140
- JANUS HENDERSON GROUP PLC added 431,733 shares (+135.0%) to their portfolio in Q2 2025, for an estimated $9,368,606
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
CORAL GABLES, Fla., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its third quarter 2025 financial results after the market close on Wednesday, November 5, 2025.
Catalyst's management team will host a conference call and webcast on Thursday, November 6, 2025, at 8:30 AM ET to discuss the Company's financial results and provide a business update.
Conference Call & Webcast Details
| Date : | November 6, 2025 |
| Time : | 8:30 AM ET |
| US/Canada Dial-in Number : | 877-407-8912 |
| International Dial-in Number : | 201-689-8059 |
The webcast will be accessible under the Investors section on the Company's website at www.catalystpharma.com . A webcast replay will be available on the Catalyst website for at least 30 days following the date of the event.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.
For more information, please visit Catalyst's website at www.catalystpharma.com .
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2024 and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
